 Brickell Biotech, Inc. Brickell BBI, a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, May 13, 2020. Brickells management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. 